Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF). COR-1167 is a once-daily subcutaneous CRF2 agonist that has demonstrated substantial protective effects and functional improvement in the heart,… Read More
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for anastrozole, to prevent breast cancer in post-menopausal women at moderate or high risk of developing the disease. The hormone treatment was already authorised for use in the treatment of breast cancer… Read More
Scientists revealed in a new study how gut bacteria contribute to the progression of advanced prostate cancers and their resistance to hormone therapy by providing an alternative source of growth-promoting androgens, or male hormones. Hormone therapy is the standard of care for advanced prostate cancer and works… Read More
